 |
|
Daily Digest
November 18, 2026
Volume 8, Issue 4
|
|
What’s Inside Today
BBB National Programs’ National Advertising Division said on November 18 that it will refer Beyond Air, Inc. to regulatory authorities after the company declined to participate in a challenge brought by competitor Vero Biotech Inc. It is the second referral announced by the self-regulatory system this week, following the National Advertising Review Board’s November 16 action involving Harry’s. Separately, FDA’s proposed rule on N-acetyl-L-cysteine (NAC) was published in the Federal Register on November 17. Publication fixes the close of the public comment period at January 19, 2027.
|
|
|
|
Today’s Lead
|
|
BBB National Programs, National Advertising Division | November 18, 2026
The National Advertising Division, the advertising review body of BBB National Programs, said on November 18 that it will refer Beyond Air, Inc. to the appropriate regulatory authorities after the company informed NAD that it would not participate in the self-regulatory process. Vero Biotech Inc. had used NAD’s Fast-Track SWIFT process to challenge claims that Beyond Air’s LungFit PH system has no logistical dependency, or materially less logistical dependency and burden, than Vero’s GENOSYL Delivery System. NAD cited Section 2.1(I)(3) of the NAD/NARB Procedures as the basis for the referral, which follows a December 2024 NAD decision recommending that Beyond Air discontinue or modify comparative safety claims for the same product line.
|
|
|
|
|
FDA and FTC Enforcement
|
|
Federal Register | November 17, 2026
FDA’s proposed NAC rule, announced on November 16 and covered in prior issues, was formally published in the Federal Register on November 17 as document 2026-23351. What is new is the deadline, with electronic or written comments in Docket FDA-2025-N-2699 due by January 19, 2027. The notice states that FDA intends to withdraw its NAC enforcement discretion guidance if the rule is finalized.
|
|
|
Your Voice Matters
FDA is accepting public comments on its proposed NAC rule through January 19, 2027 (Docket FDA-2025-N-2699). It is the agency’s first rulemaking under the exclusion provision of the dietary supplement definition.
|
|
DSHEA Preservation Alliance
Powered by PICXM
|
|